GSK Boosts Its Infectious Disease Portfolio With Brexafemme License

 
• By Joseph Haas

The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.

GSK HQ
GSK adds a novel antifungal to its infectious disease portfolio • Source: Shutterstock

More from Deals

More from Business